CDMO Samsung Biologics Signs 2nd Major Deal with GSK, Worth $296 Million
Samsung Biologics, one of the world’s largest contract development and manufacturing organizations (CDMOs), is continuing to build on what has been a productive partnership with the U.K.-based pharmaceutical company GlaxoSmithKline…